
Pharmacally
Disease & Drugs
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Disease & Drugs
Clinical TrialsIntroducing Ozempic in India: A Breakthrough in Type 2 Diabetes and Weight ManagementDecades of groundbreaking scientific discovery fuel Ozempic’s discovery journey. In the late 1970s, researchers discovered a natural hormone called glucagon-like peptide-1 (GLP-1).Fact-Checked
Clinical TrialsFDA Approves Jazz’s Zepzelca plus Roche’s Tecentriq for Extensive-Stage Small Cell Lung Cancer MaintenanceIn October 2025, the U.S. Food and Drug Administration (FDA) granted approval for the combination of Zepzelca (lurbinectedin) from Jazz Pharmaceuticals and Tecentriq (Atezolizumab) from Roche as a…Fact-Checked
Clinical TrialsFDA Approval of Rhapsido® (remibrutinib) for Chronic Spontaneous Urticaria (CSU)On 30 September 2025, The United States Food and Drug Administration (FDA) has granted approval to Rhapsido® (remibrutinib), developed by Novartis AG, for the treatment of chronic spontaneous…Fact-Checked
Drugs Safety AlertRising Cough Syrup Linked Deaths in India Put Children’s Safety in SpotlightLast couple of weeks, a series of child deaths in India has attracted nationwide attention and triggered urgent investigations.Fact-Checked
New Drug ApprovalFDA Expands Tremfya Approval to Children with Plaque Psoriasis and Psoriatic ArthritisThe U.S. Food and Drug Administration have expanded the label for TREMFYA (Guselkumab), now approving it for children six years of age and older who weigh at least…Fact-Checked
Clinical TrialsIonis’ Zilganersen Sets New Milestone in Alexander Disease with Phase 3 ResultsIonis Pharmaceuticals announced positive topline results from its pivotal Phase 1–3 trial of Zilganersen at late September 2025, through a company release.Fact-Checked
Clinical TrialsJ&J‘s Investigational Seltorexant: Comparable to Quetiapine in Depression With Insomnia, With a Safer ProfileWritten By-Pallavi Garje BPharm Reviewed By-Pharmacally Editorial Team Managing major depressive disorder (MDD) often becomes more challenging when insomnia is…Fact-Checked
Clinical TrialsSotatercept Shows Early Benefit in Pulmonary Arterial Hypertension When Added Within First Year of DiagnosisA new study published in the New England Journal of Medicine shows that the early addition of sotatercept, an investigational activin-signaling inhibitor developed by Merck, can play an…Fact-Checked
Clinical TrialsFirst-in-Human Gene Therapy AMT-130 for Huntington’s disease Reports Positive Results in Phase I/II TrialHuntington’s disease (HD) has remained one of the most challenging inherited neurological disorders, with no approved treatment to slow or stop its progression.Fact-Checked
Clinical TrialsFDA approves Palsonify (paltusotine) a once-daily oral option for adults with acromegalyThe U.S. Food and Drug Administration (FDA) has approved Palsonify (paltusotine), developed and marketed by Crinetics Pharmaceuticals, Inc., for the treatment of adults with acromegaly who have not…Fact-Checked
Clinical TrialsFDA Authorizes Essilor Stellest™ Lenses to Slow Childhood MyopiaOn September 25, 2025, the U.S. Food and Drug Administration authorized Stellest™ spectacle lenses, the first glasses in the country specifically designed to slow the progression of childhood…Fact-Checked
Clinical TrialsFDA Approves Inluriyo for ESR1-Mutated Advanced Breast CancerOn September 25, 2025, the U.S. Food and Drug Administration (FDA) approved Inluriyo (imlunestrant) for the treatment of adult patients with estrogen receptor-positive (ER+), human epidermal growth factor…Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.